James Dignam to Time Factors
This is a "connection" page, showing publications James Dignam has written about Time Factors.
Connection Strength
0.344
-
Scaling and interpreting treatment effects in clinical trials using restricted mean survival time. Clin Trials. 2025 Feb; 22(1):3-10.
Score: 0.119
-
Risk Factors for Hospital Readmission in Patients With Interstitial Lung Disease. Respir Care. 2024 04 22; 69(5):586-594.
Score: 0.029
-
Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10(2):271-278.
Score: 0.029
-
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
Score: 0.023
-
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. Int J Radiat Oncol Biol Phys. 2018 01 01; 100(1):38-44.
Score: 0.019
-
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):296-303.
Score: 0.018
-
Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 01; 33(4):332-9.
Score: 0.015
-
Assessing treatment benefit with competing risks not affected by the randomized treatment. Stat Med. 2015 Jan 30; 34(2):265-80.
Score: 0.015
-
Bayesian approach for flexible modeling of semicompeting risks data. Stat Med. 2014 Dec 20; 33(29):5111-25.
Score: 0.015
-
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24.
Score: 0.013
-
Integrated phase II/III clinical trials in oncology: a case study. Clin Trials. 2012 Dec; 9(6):741-7.
Score: 0.013
-
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011 Mar 16; 103(6):478-88.
Score: 0.012
-
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011 Apr 01; 29(10):1326-34.
Score: 0.012
-
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001 May 02; 93(9):684-90.
Score: 0.006
-
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 06; 88(21):1529-42.
Score: 0.004